FDA OKs New Frontline Endometrial Cancer Regimen, First in Decades
The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced on Monday. For adults with primary advanced or recurrent endometrial cancer that is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), dostarlimab is now approved as part of a […]
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition
CHICAGO — Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to avoid surgery, chemotherapy, and radiation, at least for the time being. All 14 patients followed for at least 6 months had clinical complete responses with no evidence […]